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planning. After 3 months a complete response was observed 
in 46%, and 7% had partial response.  
Conclusions: Using the HYPERcollar, deep hyperthermia 
treatment of HNC was found to be safe, feasible, with good 
compliance and promising outcome. These promising early 
clinical results culminated in the use of hyperthermia as a 
standard addition to reirradiation. We will now embark on a 
study for (chemo-)irradiation combined with hyperthermia in 
primary head and neck cancer.  
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Randomized controlled trials (RCTs) are the gold standard for 
comparative effectiveness research of medical interventions. 
Treatment guidelines rank evidence of using a hierarchy with 
evidence from RCTs at the highest level, Level I. Many 
authorities require Level I evidence from RCTs for 
registration and reimbursement of a new drug. When Level I 
evidence is not available, the treatment is often viewed as 
being “unproven”. Ideally, every new diagnostic or 
interventional procedure should be tested in RCTs before 
becoming standard care to avoid ineffective or harmful 
treatments. The reason is that even treatments supported by 
a clear biological rationale and strong pre-clinical data may 
not produce a therapeutic gain; examples include the 
detrimental effect of erythropoietin when used together with 
radiotherapy for head and neck cancer  or class 1c 
antiarrhythmic agents in myocardial infarction patients . The 
unexpected result of these studies provides a strong 
argument in favour of randomization.   
Engineers and physicists often tackle the problem of 
obtaining “evidence” by making models to calculate the 
quantitative relationship between parameters and a 
particular outcome. The acceptance of the latter kind of 
empirical model spring from its ability to predict the 
outcome of experiments with accuracy, reliability and 
prospective reproducibility that is sufficient to be useful. The 
analogy with human biology is far from perfect because of 
the complexity of the processes involved. In physics 
controlling a rather limited set of known experimental 
conditions will suffice to standardize outcome 
measurements. The utility of models predicting clinically 
relevant outcomes could theoretically indeed be established 
by prospective comparisons between expected and observed 
outcomes. However, this is no simple task and has not been 
accomplished convincingly in the past. Nearly all proton 
therapy studies are retrospective, with heterogeneous 
patient groups recruited over long time periods, treated with 
varying techniques and with often very incomplete follow-up 
data. The radiobiology of the complex DNA damage in the 
Bragg peak is large unexplored and is not taken into account 
in current proton TPS. Some TCP and NTCP models are 
without doubt of merit for photon therapy, but they should 
not be extrapolated blindly to proton therapy as long as the 
latter models too have undergone extensive validation. The 
model-based approach is clearly a field where much more 
research is needed before this can be accepted as an 
alternative for RCTs. Except for some quite extreme cases, 
e.g. in some CNS and childhood tumours, randomised trials 
are still necessary, scientifically, legally and for obtaining 
reimbursement.   
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Purpose / Objective: Cognitive impairment is frequently 
present in childhood brain tumour survivors and greatly 
impacts psychosocial development and quality of survival. 
Major contributing factors are related to tumour, the 
presence of hydrocephalus, surgery, chemotherapy and 
radiotherapy. The neurocognitive functions primarily involved 
are including memory, attention, visual perceptual ability 
and verbal function.  
Materials and Methods: The majority of data are essentially 
based on past treatments with varying treatment volumes 
(craniospinal irradiation followed by a boost, whole brain 
irradiation, local irradiation with varying dose prescriptions) 
for medulloblastoma, low grade glioma, ependymoma, germ 
cell tumours and leukemia. The literature is replete of data 
based on retrospective evaluations spanning many years 
during which general disease management was improved. 
Additionally, radiotherapeutic approaches considerably 
changed with the introduction of 3 D conformal technologies 
including IMRT and recently proton therapy that essentially 
permit a more precise coverage of tumour while sparing 
normal brain tissue.  
Results: Post radiation changes include a wide spectrum of 
abnormalities from subclinical changes detectable only by 
MRI to focal neurological deficits and intellectual 
impairment. It appears that all changes are likely to result 
from complex alterations within several functional 
compartments with the following contributing factors: 
damage to vessel structures, deletion of oligodendrocyte 
progenitor cells and mature oligodendrocytes (white matter), 
deletion of neural stem cell population in the hippocampus. 
Additionally, the tumours significantly differ between the 
inherent disabling potential with respect to tumour location 
and the therapeutic approach. The major risk factors are 
young age at treatment and a dose relationship in whole 
brain irradiation. Recent data indicate that particular 
radiosensitive regions of the brain are more susceptible to 
the adverse effects of radiation such as frontal lobes, 
temporal lobe and hippocampus including anatomical 
subcompartments in which neurogenesis occurs 
(subventricular zone). However, the relationship between 
radiation dose to these areas and a decline in neurocognitive 
function remains a controversial issue. Recent data indicate 
that radiation dose to neuronal progenitor cell niches and 
temporal lobes causes a decline in cognitive function. Modern 
radiotherapy technologies are able to selectively reduce the 
dose to organs at risk. Correspondingly, reducing the dose to 
the hippocampus in adults appears to preserve memory with 
conformal avoidance of the hippocampal neural stem cell 
compartment during whole-brain radiotherapy (recently 
